| abstract |
Disclosed herein are methods of preventing and treating acute GVHD and chronic GVHD following hematopoietic cell transplantation (HCT), as well as methods of enhancing in vivo expansion of donor CD8 + T cells in lymphoid tissue in vivo following HCT and post-HCT enhancement procedures Methods for Tissue Expression in Recipients of Sexual Death-Ligand 1 (PD-L1, or B7H1). The method entails administering to the recipient one or more doses of an effective amount of a therapeutic agent to temporarily deplete CD4 + T cells or reduce serum IL-2 concurrently with, immediately prior to, or immediately following HCT. Some examples include anti-CD4 antibodies or anti-CD4- meditope immunotoxins, anti-IL-2 antibodies, agents that block IL-2R, and/or PD-L1-Ig. One or more additional therapeutic agents, such as IFN-γ, can be administered. |